Streetbeat News

RHHBY

Roche Holding AG

CEO

Severin Schwan

Industry

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Open

42.57

Mkt cap

278B

Volume

213K

High

43.31

P/E Ratio

29.63

52-wk high

43.96

Low

42.56

Div yield

N/A

52-wk low

29.20

Roche's member company, Genentech, has received FDA approval for TNKase, a thrombolytic agent, for treating acute ischemic stroke in adults.

Portfolio Pulse from

March 04, 2025 | 9:15 pm

The report 'Enterprise Tech Ecosystem Series: F. Hoffmann - La Roche Ltd 2024' has been added to ResearchAndMarkets.com's offerings, focusing on Roche's digital transformation through accelerators, incubators, and innovation programs.

Portfolio Pulse from

March 03, 2025 | 11:30 am

Roche's Xolair shows promising results in a Phase III study, proving more effective and with fewer side effects than oral immunotherapy for food allergies.

Portfolio Pulse from

March 02, 2025 | 10:15 pm

The European Medicines Agency's CHMP has recommended the approval of Roche's Columvi in combination with GemOx for treating relapsed or refractory diffuse large B-cell lymphoma. This could offer a new treatment option for patients ineligible for stem cell transplants.

Portfolio Pulse from

February 28, 2025 | 1:30 pm

Roche's Q4 results highlight its resilience and strategic advancements, with strong sales from Ocrevus and Vabysmo. The company also introduced new sequencing technology and has a promising late-stage pipeline, making it a buy.

Portfolio Pulse from

February 27, 2025 | 2:00 am

Roche has introduced a new sequencing technology called sequencing by expansion (SBX), which promises ultra-rapid, high-throughput sequencing. This innovation could significantly impact the next-generation sequencing market.

Portfolio Pulse from

February 20, 2025 | 6:45 pm

The FDA has approved Genentech's Evrysdi tablet, the first and only tablet for treating spinal muscular atrophy (SMA). This approval marks a significant advancement as Evrysdi is the only non-invasive disease-modifying treatment for SMA.

Portfolio Pulse from

February 12, 2025 | 5:00 pm

The FDA has approved Roche's Evrysdi tablet, making it the first and only tablet for treating Spinal Muscular Atrophy (SMA). This approval marks a significant advancement as Evrysdi is a non-invasive, disease-modifying treatment for SMA.

Portfolio Pulse from

February 12, 2025 | 5:00 pm

Genentech's Gazyva shows significant improvement in treating active lupus nephritis, according to a Phase III trial published in the New England Journal of Medicine.

Portfolio Pulse from

February 07, 2025 | 9:00 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.